ArticleParkinson's disease2015
Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study.
Article in Parkinson's disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.Internal medicine (Tokyo, Japan)Trial
- Pathophysiology and pharmacological management for sleep problems in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Restless legs syndrome in Parkinson's disease: epidemiology, pathogenetic overlaps, and clinical management.Journal of neurology · 2025Review
- Effects of rotigotine on sleep in Parkinson's disease patients: a Parkinson's KinetiGraph study.Frontiers in neurology · 2025Article
- Impact of Physical Exercise on Levodopa Therapy Across Parkinson's Disease Stages.Journal of Parkinson's disease · 2024Article
- Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Management of Sleep Disturbances in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.CNS drugs · 2021Review
- Therapies for Restless Legs in Parkinson's Disease.Current treatment options in neurology · 2019Review
- Rotigotine Transdermal Patch: A Review in Parkinson's Disease.CNS drugs · 2019Review
- Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease.Chinese medical journal · 2018Article
- Review
- An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.Sleep & breathing = Schlaf & Atmung · 2017Observational
- Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now?NPJ Parkinson's disease · 2017Review
- New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.Current pharmacology reports · 2016Article
- Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording.Parkinson's disease · 2016Article
- Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome - patient considerations.Degenerative neurological and neuromuscular disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep disturbances occur frequently in patients with Parkinson's disease (PD). The aim of this study was to investigate the effects of rotigotine on sleep fluctuations in a sample of PD patients with self-reported complaints of nocturnal awakenings. This prospective, open-label, observational, and multicenter study enrolled consecutive outpatients with PD and administered rotigotine (mean dose 8.9 mg/day) for 3 months. The primary endpoint was the change from baseline in sleep fragmentation, assessed using the sleep maintenance subscale score of the Parkinson's Disease Sleep Scale (PDSS). The newly designed Parkinson's Disease Sleep Fragmentation Questionnaire (PD-SFQ) was used to measure other sleep parameters. A total of 62 patients were enrolled (mean age 70.2 years; 66% male). At 3 months, rotigotine significantly improved sleep fragmentation from baseline on the PDSS-2 sleep maintenance subscale (from 3.4 ± 0.9 to 1.9 ± 1.4; P < 0.0001). Rotigotine also significantly improved nocturnal motor symptoms (P < 0.0001), restless legs-like symptoms (P < 0.005), and nocturia (P = 0.004). Rotigotine significantly improved self-reported complaints of sleep fragmentation in PD patients and could be a useful treatment to improve this specific sleep problem in PD. However, these results are based on a small and clinically heterogeneous sample so they must be taken cautiously.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.